Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)
Study Details
Study Description
Brief Summary
To develop a repository of blood samples from patients with ILD to support future studies into the development of such biomarkers. Patients with pneumonia and healthy patients will also be recruited as a control group.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
The proposed biospecimen repository would be derived from patients diagnosed with ILD. This is to include 500 patients in the repository, with each patient contributing one blood sample. Patients with pneumonia and healthy patients will also be recruited as a control group.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
ILD 250 patients (male and females >18 years of age) with the diagnosis of fibrotic DILD (IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis. |
Other: ILD
100 cc of blood collected from a total of 250 ILD patients. This includes IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20)), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis
|
Healthy 100 healthy participants as a control group. |
Other: Healthy
100 cc of blood collected from a total of 25 healthy volunteers in order to compare with the ILD participants.
|
Pneumonia 25 patients with pneumonia as a control group. |
Other: Pneumonia
100 cc of blood collected from a total of 100 participants with a diagnosis of pneumonia in order to compare with the ILD participants.
|
Outcome Measures
Primary Outcome Measures
- Future Disease Management [1 visit]
Reliable biomarkers to help guide treatment in ILD would be a major step forward in the management of this disease.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients with a diagnosis of ILD or any fibrotic disease of the lung or a diagnosis of pneumonia
-
Patients willing to provide written informed consent
Exclusion Criteria:
- Unwillingness/unable to give blood samples
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Mayo Clinic | Rochester | Minnesota | United States | 55905 |
Sponsors and Collaborators
- Mayo Clinic
Investigators
- Principal Investigator: Eva M Carmona Porquera, MD, PhD, Mayo Clinic
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 17-008088